Amol Akhade, Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, posted on X:
“Tislelizumab gets FDA approval for Metastatic Gastric or GE junction adenocarcinoma Her2 negative with PDL1 More than 1 %. This is based upon rationale 305 trial. One more option of IO in this space where pembrolizumab and nivo are already approved irrespective of PDL1.”
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant.